Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Hemost 2005; 3: 1800.
Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasgrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66. e9.
Uchiyama S. Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment. Cardiovasc Therap. In press 2010.
O’Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasgrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention. J Am Coll Cardiol 2009; 54: 678.
Wallentin L, Becker RC, Budaj A, et al. Ticargrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045.